Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor
5
$ 9.99
In stock
(796)
Product Description
Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021, Journal of Hematology & Oncology
Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer
Emerging new therapeutic antibody derivatives for cancer treatment
Tumor necrosis factor - Wikipedia
An orally active, small-molecule TNF inhibitor that disrupts the homotrimerization interface improves inflammatory arthritis in mice
An orally active, small-molecule TNF inhibitor that disrupts the homotrimerization interface improves inflammatory arthritis in mice
A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer's disease mouse model
TNF-α: The shape of small molecules to come? - ScienceDirect
Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor
Small molecule inhibitors as emerging cancer therapeutics
Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer
Frontiers An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis
